Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Novo Nordisk has announced that users will be able ... Personally, I expect great results from this partnership in the future. Honestly, in my opinion, practically nothing has changed since ...

FDA seizes hundreds of fake Ozempic units from US supply after Novo Nordisk alerts regulators to counterfeit semaglutide ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.

Septerna will also get royalties on any future product sales, The Wall Street Journal reported. Novo Nordisk will pay all the research and development costs for the project. The U.S. biotech ...

Teens are being prescribed Ozempic more than ever before — and some doctors are worried about what the trend could mean.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), Novo Nordisk A/S ...

Novo Nordisk announced Friday that Lars Fruergaard ... This doesn’t mean the company’s future isn’t bright—they remain a leader in an expanding category with tremendous growth potential.

"The way we know Novo Nordisk is that normally you have patience ... it is essential that the board has a clear plan for the future." "Novo is making a change in leadership as they feel they ...